February 2024 Br J Cardiol 2024;31:28–30 doi:10.5837/bjc.2024.007
Peter S Giannaris, Viren S Sehgal, Branden Tejada, Kenzy H Ismail, Roshan Pandey, Eamon Vega, Kathryn Varghese, Ahmed K Awad, Adham Ahmed, Irbaz Hameed
Introduction Individuals with bicuspid aortic valves (BAV) are at an elevated risk for developing aortic stenosis.1 Currently, transcatheter aortic valve replacement (TAVR) has emerged as a less invasive alternative to surgical aortic valve replacement (SAVR), demonstrating non-inferior to superior outcomes across patients of various risk levels.2 Less clear, however, are the outcomes of these modalities in BAV patients, as this population has been relatively underrepresented in many large studies. Due to the growing use of TAVR, we performed an updated pairwise meta-analysis on TAVR in comparison to SAVR in patients with BAV. Method This stu
September 2023 Br J Cardiol 2023;30:95–8 doi:10.5837/bjc.2023.025
Riccardo Proietti, Mark Field, Victoria McKay, Gregory Y H Lip, Manoj Kuduvalli, on behalf of UK Aortic Society
Introduction The diseases of the aorta are an important cause of worldwide cardiovascular mortality and morbidity.1 Hospital admissions within the UK at the end of 2010 were identified as 8.8 for thoracic aortic dissections and 9.0 for thoracic aortic aneurysms, per 100,000 inhabitants.2 More recently, significant regional variation has been documented in access to treatment and mortality outcomes in the UK.3 These authors speculated that one of the barriers to treatment underlying this unwarranted variation was a lack of clear guidelines on population screening for this disease. Aneurysms of the thoracic aorta commonly have a genetic basis
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits